A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients.
BACKGROUND: The marked excess in cardiovascular mortality that results from uremia remains poorly understood.
METHODS AND RESULTS: In 2 independent, nested case-control studies, we applied liquid chromatography-mass spectrometry-based metabolite profiling to plasma obtained from participants of a large cohort of incident hemodialysis patients. First, 100 individuals who died of a cardiovascular cause within 1 year of initiating hemodialysis (cases) were randomly selected along with 100 individuals who survived for at least 1 year (controls), matched for age, sex, and race. Four highly intercorrelated long-chain acylcarnitines achieved the significance threshold adjusted for multiple testing (P
CONCLUSIONS: Our data highlight clinically meaningful alterations in acylcarnitine homeostasis at the time of dialysis initiation, which may represent an early marker, effector, or both of uremic cardiovascular risk.
|Year of Publication||
J Am Heart Assoc
2013 Dec 05
|PubMed Central ID||
K08 DK090142 / DK / NIDDK NIH HHS / United States
K24 DK094872 / DK / NIDDK NIH HHS / United States
K08-DK-090142 / DK / NIDDK NIH HHS / United States
R21-DK-071674 / DK / NIDDK NIH HHS / United States